6:19 PM
 | 
Apr 24, 2007
 |  BC Extra  |  Clinical News

Pharmos up on Phase IIa pain data

PARS gained $0.29 (19%) to $1.79 on Tuesday after the lowest dose of intravenous cannabinor (12 mg) met the primary endpoint of a significant decrease in...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >